Psilocybin for Tobacco Addiction: The Hopkins Smoking Cessation Data

Psilocybin for Tobacco Addiction: The Hopkins Smoking Cessation Data

The Johns Hopkins psilocybin smoking cessation study produced results that, by the standards of addiction pharmacology, were extraordinary: 80% of participants were biologically verified as tobacco-abstinent at 6-month follow-up. For context, the best-performing pharmacological aids for smoking cessation (varenicline/Chantix) produce approximately 35% abstinence at 6 months. NRT (nicotine replacement therapy) produces roughly 25%. The psilocybin results, if they hold at scale, represent the most effective smoking cessation intervention ever studied.

The Research: Matthew Johnson et al., Johns Hopkins

Study design: A 2014 pilot study (published in Psychopharmacology) with 15 participants who smoked an average of 19 cigarettes per day for 31 years. All had made multiple serious quit attempts with other methods. The treatment was not psilocybin alone — it was psilocybin combined with CBT-based behavioral cessation support.

Protocol:

• Several weeks of CBT-based cessation counseling with a target quit date set
• Two to three psilocybin sessions (20 and 30mg psilocybin equivalents, with an optional third session at 30mg)
• Sessions began around the quit date
• Integration sessions following each psilocybin dose

Results:

• 80% biologically verified abstinence at 6-month follow-up
• 67% abstinence at 12-month follow-up (remarkable — most smoking cessation rates decline significantly over time)
• At 2.5-year follow-up: 60% still abstinent

Limitations: The study was a pilot — 15 participants, no control group, open-label design. The results cannot definitively attribute the effect to psilocybin rather than expectancy, the therapeutic relationship, or the CBT component. A Phase 2 randomized controlled trial is needed.

Current status (2026): Matthew Johnson's group at Hopkins received NIDA funding for a Phase 2 randomized trial. Results are anticipated in 2026-2027.

Why Psilocybin Might Help With Nicotine Addiction

Interrupting addiction-related identity: Many people who smoke are deeply attached to their smoker identity — smoking is tied to who they are, how they manage stress, how they socialize. Psilocybin experiences, particularly the ego-dissolution and perspective-shift associated with higher doses, may disrupt this identity attachment more effectively than behavioral interventions alone.

Meaning and motivation: The Hopkins cessation participants frequently reported that their psilocybin sessions produced profound encounters with the question of what they value — their health, relationships, and future. These encounters appeared to shift the motivational basis for quitting from obligation to genuine desire.

Neuroplasticity: Nicotine addiction involves reinforcement of neural pathways. Psilocybin's documented neuroplasticity effects — BDNF upregulation, synaptogenesis, synaptic flexibility — may create a window in which new habits and responses form more readily.

The Mystical Experience Factor: Across psilocybin research, the depth of mystical-type experience during the session predicts therapeutic outcomes. In the smoking study, participants who rated their sessions as complete mystical experiences showed the highest abstinence rates. This finding is consistent across addiction, depression, and anxiety research.

The Hopkins Protocol in Detail

Preparation (weeks 1–4):

• CBT-based smoking cessation counseling (behavioral strategies, coping skills, motivation enhancement)
• Relationship-building with the two-person facilitator team (therapy is conducted by a therapist-researcher pair)
• Identification of personal goals and values related to quitting
• Setting of target quit date (approximately week 5)

Psilocybin sessions:

• Session 1 (20mg): At or just after the quit date. The first session is lower dose to familiarize participants with the experience.
• Session 2 (30mg): Approximately 2 weeks later, at higher dose for deeper work.
• Optional Session 3 (30mg): Available if clinical judgment suggests benefit.

Each session:

• Begins in the morning, lasts 6–7 hours
• Eye mask and headphones with Johns Hopkins playlist
• Two trained facilitators present throughout
• Integration discussion at session close

Integration (weeks following each session):

• Processing sessions with the facilitators
• Connecting session content to the cessation work
• Supporting the behavioral changes identified during sessions

Who Is This Most Likely to Help

Based on the pilot data and what we know about psilocybin's mechanism:

Most likely to benefit:

• People who have tried multiple quit methods and failed
• People who are heavily identified as "smokers" — where identity is a core barrier
• People who are motivated but can't sustain motivation long-term
• People who are open to the psilocybin experience and can engage meaningfully with it

Less clear benefit:

• People who smoke primarily as a physiological addiction without significant psychological component (though this group is smaller than often assumed)
• People with contraindications to psilocybin (psychosis history, bipolar I, lithium use)

Current Access Options

Clinical trials: The most rigorous path. If the Hopkins Phase 2 trial is recruiting, eligible participants receive psilocybin-assisted treatment at no cost. Check clinicaltrials.gov for active smoking cessation psilocybin trials.

Oregon service centers: Legal psilocybin facilitation is available in Oregon for adults 21+. Bringing a cessation-focused intention to a session is possible. However, the CBT behavioral support component of the Hopkins protocol is not automatically included — pairing with a cessation counselor or therapist is recommended.

Combining approaches: There is no known pharmacological reason that psilocybin cannot be combined with nicotine replacement therapy (NRT) or bupropion. Varenicline (Chantix) may have some interaction through nicotinic receptor mechanisms — discuss with a physician if using varenicline around a psilocybin session.

Comparison to Other Cessation Methods

| Method | 6-Month Abstinence Rate (Approximate) | |--------|--------------------------------------| | Cold turkey (no aid) | 5–10% | | NRT (patch, gum) | 15–25% | | Bupropion (Wellbutrin/Zyban) | 20–30% | | Varenicline (Chantix) | 30–35% | | Psilocybin + CBT (Hopkins pilot) | 80% |

The comparison is imperfect — the Hopkins study was small and uncontrolled. But the magnitude of the difference suggests something real is happening that warrants the Phase 2 trial.

What This Means for Addiction Research

The smoking cessation data is perhaps the most accessible demonstration of psilocybin's potential in addiction treatment because it:

• Has measurable, biological outcomes (carbon monoxide testing for tobacco abstinence)
• Addresses a very common, widely understood addiction
• Compares favorably to established treatments whose efficacy is well-documented

The same research group is studying psilocybin for alcohol use disorder and cocaine use disorder, with comparably compelling early results. Tobacco was likely chosen as a first research target precisely because it's socially and politically less contested than other addictions — a strategic choice that has produced the clearest public evidence of psilocybin's addiction potential.